1. Home
  2. CAL vs FHTX Comparison

CAL vs FHTX Comparison

Compare CAL & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caleres Inc.

CAL

Caleres Inc.

HOLD

Current Price

$12.32

Market Cap

400.3M

ML Signal

HOLD

Logo Foghorn Therapeutics Inc.

FHTX

Foghorn Therapeutics Inc.

HOLD

Current Price

$4.68

Market Cap

332.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAL
FHTX
Founded
1878
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Shoe Manufacturing
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
400.3M
332.2M
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
CAL
FHTX
Price
$12.32
$4.68
Analyst Decision
Buy
Strong Buy
Analyst Count
2
8
Target Price
$15.00
$11.50
AVG Volume (30 Days)
697.9K
149.7K
Earning Date
05-28-2026
05-13-2026
Dividend Yield
2.56%
N/A
EPS Growth
N/A
25.32
EPS
N/A
N/A
Revenue
$85,513,000.00
$30,909,000.00
Revenue This Year
$6.10
$16.83
Revenue Next Year
$1.09
$15.06
P/E Ratio
N/A
N/A
Revenue Growth
0.46
36.75
52 Week Low
$8.80
$3.14
52 Week High
$17.53
$6.95

Technical Indicators

Market Signals
Indicator
CAL
FHTX
Relative Strength Index (RSI) 63.02 42.49
Support Level $11.71 $4.42
Resistance Level $13.55 $5.79
Average True Range (ATR) 0.69 0.31
MACD 0.20 0.03
Stochastic Oscillator 95.63 39.80

Price Performance

Historical Comparison
CAL
FHTX

About CAL Caleres Inc.

Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - famous Footwear and Brand Portfolio. The famous Footwear segment is comprised of its famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The famous Footwear segment operated around 846 stores at the end of 2024. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. Geographically, the company generates the majority of its revenue from Domestic operations.

About FHTX Foghorn Therapeutics Inc.

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Share on Social Networks: